Asynchronous pineoblastoma is more likely after early diagnosis of retinoblastoma: a meta-analysis.

Marcus C de Jong, Furqan Shaikh, Brenda Gallie, Wijnanda A Kors, Robin W Jansen, Charlotte Dommering, Pim de Graaf, Annette C Moll, Helen Dimaras, Manohar Shroff, Tero T Kivelä, Sameh E Soliman

Journal: Acta ophthalmologica 2022;100(1):e47-e52

PMID: 33939299

Abstract

PURPOSE

To determine the risk of patients with an early diagnosis of heritable retinoblastoma being diagnosed with TRb (or pineoblastoma) asynchronously in a later stage and its effect on screening.

METHODS

We updated the search (PubMed and Embase) for published literature as performed by our research group in 2014 and 2019. Trilateral retinoblastoma (TRb) patients were eligible for inclusion if identifiable as unique and the age at which TRb was diagnosed was available. The search yielded 97 new studies. Three new studies and eight new patients were included. Combined with 189 patients from the previous meta-analysis, the database included 197 patients. The main outcome was the percentage of asynchronous TRb in patients diagnosed before and after preset age thresholds of 6 and 12 months of age at retinoblastoma diagnosis.

RESULTS

Seventy-nine per cent of patients with pineoblastoma are diagnosed with retinoblastoma before the age of 12 months. However, baseline MRI screening at time of retinoblastoma diagnosis fails to detect the later diagnosed pineal TRb in 89% of patients. We modelled that an additional MRI performed at the age of 29 months picks up 53% of pineoblastomas in an asymptomatic phase. The detection rate increased to 72%, 87% and 92%, respectively, with 2, 3 and 4 additional MRIs.

CONCLUSIONS

An MRI of the brain in heritable retinoblastoma before the age of 12 months misses most pineoblastomas, while retinoblastomas are diagnosed most often before the age of 12 months. Optimally timed additional MRI scans of the brain can increase the asymptomatic detection rate of pineoblastoma.

© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

Address: Department of Radiology and Nuclear Medicine, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Pediatric Hematology and Oncology, University of Toronto, Toronto, ON, Canada.; Department of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada.; Department of Ophthalmology and Vision Science, The Hospital for Sick Children, Toronto, ON, Canada.; Department of Pediatric Oncology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Clinical Genetics, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Department of Ophthalmology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Child Health Evaluative Sciences Program, SickKids Research Institute, Toronto, ON, Canada.; Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.; Division of Pediatric Neuroradiology, The Hospital of Sick Children, Toronto, ON, Canada.; Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Department of Ophthalmology and Vision Science, Ocular Oncology service, Princess Margaret Hospital, Toronto, ON, Canada.; Faculty of Medicine, Department of Ophthalmology, University of Alexandria, Alexandria, Egypt.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.